drugset / Trial / NCT06058130
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
RandomizedParallel-groupSingle-blindPrevention
Summary
The goal of this clinical trial is to compare the safety and effectiveness of anticoagulation combined with antiplatelet therapy in acute ischemic stroke (AIS) patients with concomitant non-valvular atrial fibrillation (NVAF) and extracranial/intracranial artery stenosis. Participants will be 1:1 randomized into anticoagulation alone or anticoagulation combined with antiplatelet therapy. The primary endpoint is composite events 3 months after enrollment.
Timeline
- Start
- 2023-09-29
- Primary completion
- 2025-10-01
- Completion
- 2026-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 100 mg | — |
| Subject | Cilostazol | Small molecule | 100 mg | — |
| Subject | Clopidogrel | Small molecule | 75 mg | — |
| Comparator | Dabigatran | Unknown | 110 mg | Oral |
| Comparator | Dabigatran | Unknown | 150 mg | Oral |
| Comparator | Rivaroxaban | Other / unclassified | 10 mg | Oral |
| Comparator | Rivaroxaban | Other / unclassified | 15 mg | Oral |
| Comparator | Rivaroxaban | Other / unclassified | 20 mg | Oral |
| Subject | Ticagrelor | Small molecule | 90 mg | — |